Sistema de Salut de Catalunya
Institut Català de la Salut
[Liu MC] Divisions of Allergy and Clinical Immunology, Pulmonary and Critical Care Medicine, Johns Hopkins Asthma and Allergy Center, Baltimore, MD, USA. [Chipps B] Capital Allergy and Respiratory Disease Center, Sacramento, CA, USA. [Munoz X] Servei de Pneumologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Ciber Enfermedades Respiratorias, Madrid, Spain. [Devouassoux G] Service de Pneumologie, Hôpital de la Croix Rousse, Hospices Civils de Lyon, UCB Lyon, Lyon, France. [Bergna M] Respiratory Research, CEMER, Vicente Lopez, Buenos Aires, Argentina. [Smith SG] Respiratory Therapeutic Area, GSK, Research Triangle Park, NC, USA
Vall d'Hebron Barcelona Hospital Campus
2022-01-13T17:33:32Z
2022-01-13T17:33:32Z
2021-05-10
Asma; Tractament de l'asma; Eosinòfils
Asma; Tratamiento del asma; Eosinófilos
Asthma; Asthma treatment; Eosinophils
Background The OSMO study assessed the efficacy of switching to mepolizumab in patients with severe eosinophilic asthma that was uncontrolled whilst receiving omalizumab. The objective of this analysis was to assess the proportion of patients achieving pre-defined improvements in up to four efficacy outcomes and the relationship between patient baseline characteristics and treatment response. Methods This was a post hoc analysis of OSMO study data (GSK ID:204471; ClinicalTrials.gov No. NCT02654145). Patients with severe eosinophilic asthma uncontrolled by high-dose inhaled corticosteroids, other controller(s) and omalizumab subcutaneously (≥ 4 months) were switched to mepolizumab 100 mg administered subcutaneously. Endpoints included the proportion of responders—i.e. patients achieving a pre-defined clinical improvement in ≥ 1 of the following outcomes: (1) Asthma Control Questionnaire (ACQ)-5 score (≥ 0.5-points), (2) St George’s Respiratory Questionnaire (SGRQ) total score (≥ 4-points), (3) pre-bronchodilator forced expiratory volume in 1s (FEV1; ≥ 100 mL), all at Week 32, and (4) annualised rate of clinically significant exacerbations (≥ 50% reduction). Results Of the 145 patients included, 94%, 83%, 63% and 31% were responders for ≥ 1, ≥ 2, ≥ 3 and 4 outcomes, respectively; 75% and 78% were ACQ-5 and SGRQ score responders, and 50% and 69% were FEV1 and exacerbation responders. Subgroup analyses demonstrated improvements irrespective of baseline blood eosinophil count, prior omalizumab treatment regimen/duration, comorbidities, prior exacerbation history, maintenance oral corticosteroid use, ACQ-5 and SGRQ scores, and body weight/body mass index. Conclusions After switching to mepolizumab, almost all patients with uncontrolled severe eosinophilic asthma on omalizumab achieved a beneficial response in ≥ 1 clinical outcome. Improvements were observed regardless of baseline characteristics.
This post hoc analysis and the parent study (GSK ID: 204471; ClinicalTrials.gov number: NCT02654145) were funded by GSK.
Article
Published version
English
Asma - Tractament; Eosinofília; Avaluació de resultats (Assistència sanitària); DISEASES::Respiratory Tract Diseases::Lung Diseases::Pulmonary Eosinophilia; Other subheadings::Other subheadings::Other subheadings::/drug therapy; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Drug Therapy::Drug Prescriptions::Drug Substitution; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome; ENFERMEDADES::enfermedades respiratorias::enfermedades pulmonares::eosinofilia pulmonar; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::farmacoterapia::prescripciones de medicamentos::sustitución de medicamentos; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento
BMC
Respiratory Research;22
https://doi.org/10.1186/s12931-021-01733-9
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3439]
